Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection
- 1 April 1999
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 6 (4) , 660-666
- https://doi.org/10.1038/sj.gt.3300864
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 38 references indexed in Scilit:
- Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agentGene Therapy, 1998
- Efficient Transduction of Human Hematopoietic Cells with the Human Multidrug Resistance Gene 1 via SV40 PseudovirionsHuman Gene Therapy, 1998
- Inhibition of Human Immunodeficiency Virus Replication and Growth Advantage of CD4+T Cells from HIV-Infected Individuals That Express Intracellular Antibodies Against HIV-1 gp120 or TatHuman Gene Therapy, 1998
- Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cellsGene Therapy, 1997
- Conference Summary: Novel HIV Therapies—From Discovery to Clinical Proof of ConceptAIDS Research and Human Retroviruses, 1996
- Clinical Significance of Drug Resistance in Human Immunodeficiency VirusClinical Infectious Diseases, 1995
- Genetic therapies for HIV infectionsAIDS, 1995
- Molecular and Virological Effects of Intracellular Anti-Rev Single-Chain Variable Fragments on the Expression of Various Human Immunodeficiency Virus-1 StrainsHuman Gene Therapy, 1994
- Gene Therapy for Human Immunodeficiency Virus Infection: Genetic Antiviral Strategies and Targets for InterventionHuman Gene Therapy, 1994
- The HIV-1 Protease as a Therapeutic Target for AIDSAIDS Research and Human Retroviruses, 1992